BRAF-targeted therapy alters the functions of intratumoral CD4+ T cells to inhibit melanoma progression

OncoImmunology

Volumn 3, Issue 6, 2014, Pages

  Ho, Ping Chih ^a   Kaech, Susan M ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

BRAF; CD40l; IFN ; Melanoma; T cell

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; GAMMA INTERFERON; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; VEMURAFENIB;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INNATE IMMUNITY; MELANOMA; NONHUMAN; PHARMACOLOGICAL BLOCKING; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84906507149     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.29126     Document Type: Article

References (9)

1. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694-703; PMID:23020132; http://dx.doi.org/10.1056/NEJMoa1210093
2. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012; 11:873-86; PMID:23060265; http://dx.doi. org/10.1038/nrd3847
3. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/ science.1129139
4. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 2011; 25:2559-72; PMID:22190457; http://dx.doi.org/10.1101/ gad.169029.111
5. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12:237-51; PMID:22437869; http://dx.doi.org/10.1038/nrc3237
6. Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, et al. Host immunity contributes to the antimelanoma activity of BRAF inhibitors. J Clin Invest 2013; 123:1371-81; PMID:23454771; http://dx.doi. org/10.1172/JCI66236
7. Ho PC, Meeth KM, Tsui YC, Srivastava B, Bosenberg MW, Kaech SM. Immune-based antitumor effects of BRAF Inhibitors rely on signaling by CD40L and IFNγ. Cancer Res 2014; In press; http://dx.doi. org/10.1158/0008-5472.CAN-13-3461
8. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr., You MJ, DePinho RA, McMahon M, Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41:544-52; PMID:19282848; http:// dx.doi.org/10.1038/ng.356
9. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013; 23:277-86; PMID:23518347; http://dx.doi. org/10.1016/j.ccr.2013.02.013